Cagrilintide (2.5mg) / GLP-1 S
This is a combination product, not a single compound, so it carries no evidence grade or female-evidence block of its own. Female evidence is reviewed per ingredient, follow the linked profiles below. We don't combine or invent evidence for blends.
Overview
This preparation is a research blend of two synthetic peptides supplied together in a single lyophilized vial for in-vitro and laboratory use only. It combines cagrilintide, a long-acting analogue of the pancreatic hormone amylin, with a GLP-1 analogue, an incretin-mimetic peptide. Pairing the two provides a tool for studying amylin-receptor and GLP-1-receptor signaling within a single experimental system.
Each component has been studied separately as a research material: cagrilintide for its activity at amylin and calcitonin receptors and its role in satiety and nutrient-sensing pathways, and GLP-1 analogues for their engagement of the incretin axis. Researchers examining energy-balance and glucose-regulation biology have used blends of this kind to characterize how the two receptor systems interact in preclinical and cell-based models.
Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.
Summary
FOR RESEARCH PURPOSES ONLY. Not for human or veterinary use. Not for use in food products.
Free research guide
How to tell real female data from male-extrapolated claims, with the questions to ask about any compound.
Related peptides
Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.